2012
DOI: 10.4161/hv.20903
|View full text |Cite
|
Sign up to set email alerts
|

Novel developments in the mechanisms of immune tolerance to allergens

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
4
0

Year Published

2014
2014
2023
2023

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 95 publications
(121 reference statements)
0
4
0
Order By: Relevance
“…In fourth place, within weeks to months, a dose-dependent increase in allergen-specific IgG4 is observed (58). These allergen-specific IgG4 antibodies are supposed to act as blocking antibodies interacting at the level of IgE-mediated effector cell activation (49,(59)(60)(61)(62). In particular, IL-10 produced by allergen-specific T regulatory cells and B regulatory cells has been linked to IgG4 (63).…”
Section: Time (Y)mentioning
confidence: 99%
See 1 more Smart Citation
“…In fourth place, within weeks to months, a dose-dependent increase in allergen-specific IgG4 is observed (58). These allergen-specific IgG4 antibodies are supposed to act as blocking antibodies interacting at the level of IgE-mediated effector cell activation (49,(59)(60)(61)(62). In particular, IL-10 produced by allergen-specific T regulatory cells and B regulatory cells has been linked to IgG4 (63).…”
Section: Time (Y)mentioning
confidence: 99%
“…Allergen-specific IgE increases within the first weeks to months of specific immunotherapy (2, 68) and decreases in many cases later on. The drop in specific IgE does not correlate with clinical improvement (69) and is not a suitable marker to be used for therapy monitoring or to evaluate SIT efficacy (49). This dissociation of events has been linked to long-living IgE-secreting plasma cells that survive in bone marrow and spleen (70).…”
Section: Time (Y)mentioning
confidence: 99%
“…It also suppresses the antigen-presenting capabilities to Th1 and Th2 of monocytes and APCs by down-regulating their expression of the class II major histocompatibility complex (MHC II) ( 95 ) and the co-stimulatory molecules CD54 (intercellular adhesion molecule-1, ICAM-1), CD80 and CD56 ( 96 99 ). Moreover, it can act on CD4+ T cells by inhibiting their antigen-specific activation and proliferation in lymph nodes, limiting their secretion of cytokines, such as IL-2, IFN-γ, IL-4, IL-5 and TNF-α, and their cytotoxic activity ( 45 , 100 , 101 ) and inducing their long-term anergy through the block of CD28 co-stimulatory signaling ( 102 , 103 ). Therefore, through these coordinated actions, IL-10 leads to the shutdown of the inflammatory immune response, both directly, by the suppression of macrophages and dendritic cells activity, and indirectly, by limiting T cells activation, differentiation and effector function and promoting peripheral tolerance ( 43 , 96 ).…”
Section: Il-10 Systemic Effectsmentioning
confidence: 99%
“…59 . The involvement of acquired immunity and regulatory T-cells in allergy and in immnotherapy with allergens or anti-IgE moAbs, has been reviewed elsewhere, 56,[60][61][62][63] while a thorough role of basophils appears yet unclear. Immune tolerance induced by AIT should involve these mechanisms and dampen basophil response to allergen by a T-cell mediated mechanism.…”
mentioning
confidence: 99%